Methimazole (Tapazole) Guide: Uses, Dosage, Side Effects & Affordable Generic Options for Hyperthyroidism

Methimazole is the cornerstone pharmacological treatment for hyperthyroidism — a condition that affects roughly 1.2% of the US population and disproportionately impacts women, particularly in the 20 to 50 age range. As the go-to antithyroid drug recommended in guidelines from the American Thyroid Association and the European Thyroid Association, methimazole occupies a unique position in endocrine medicine: it is the only oral medication that directly reduces thyroid hormone production, making it indispensable for managing Graves’ disease, toxic multinodular goiter, and thyrotoxicosis.

Yet the cost of consistent methimazole therapy — especially for uninsured or underinsured patients who must pay out of pocket in the United States — can present a significant burden. While brand-name Tapazole once carried premium pricing, the availability of methimazole as a generic and the dramatic price advantage offered by Indian generic manufacturers have transformed the economics of antithyroid therapy for cost-conscious patients. This guide provides a comprehensive, evidence-based overview of methimazole: its mechanism, approved and off-label uses, dosing strategies, side effect monitoring protocols, and practical considerations for accessing affordable generic options.

What Is Methimazole?

Methimazole is a thionamide-class antithyroid drug that was first introduced in the 1950s and has since become the first-line pharmacologic therapy for hyperthyroidism in most of the world. It is available as an oral tablet, typically in 5mg, 10mg, and 20mg strengths. The brand-name formulation, Tapazole, was historically marketed by various manufacturers, but today methimazole is primarily available as a generic medication produced by numerous pharmaceutical companies worldwide.

In India, methimazole is manufactured by multiple generic pharmaceutical companies and is available both as a standalone generic tablet and under various brand names. The Indian generic manufacturing ecosystem for antithyroid drugs is well-established, with reputable manufacturers producing methimazole that meets international quality standards. For patients seeking cost-effective access to consistent antithyroid therapy, these generic options can provide substantial savings compared to US pharmacy pricing.

Methimazole’s position as the preferred antithyroid drug over propylthiouracil (PTU) is based on its superior safety profile — particularly a much lower risk of severe hepatotoxicity. PTU carries a black-box warning for liver failure and is now reserved primarily for specific situations: first-trimester pregnancy, thyroid storm, or when methimazole is not tolerated. For virtually all other hyperthyroidism treatment scenarios, methimazole is the recommended first-line agent.

Mechanism of Action: Blocking Thyroid Hormone Production at the Source

Methimazole works through a targeted inhibition of thyroid peroxidase (TPO), the enzyme that catalyzes the key steps in thyroid hormone biosynthesis. The thyroid gland produces two primary hormones — thyroxine (T4) and triiodothyronine (T3) — and methimazole interferes with their production through several interconnected mechanisms:

• Inhibition of thyroid peroxidase (TPO): TPO is the rate-limiting enzyme in thyroid hormone synthesis. It catalyzes the oxidation of iodide to iodine, the iodination of tyrosine residues on thyroglobulin (forming monoiodotyrosine, MIT, and diiodotyrosine, DIT), and the coupling of MIT and DIT to form T3 and T4. Methimazole inhibits all three of these TPO-dependent reactions, effectively shutting down new hormone production.
• Blocking organification of iodine: Without TPO activity, dietary iodine cannot be incorporated into thyroglobulin. This prevents the formation of the hormone precursors (MIT and DIT) from which T3 and T4 are synthesized.
• Inhibiting coupling reactions: Even if some iodinated tyrosines are formed, methimazole interferes with their coupling into T3 (one DIT + one MIT) and T4 (two DIT molecules). This dual blockade — at both the iodination and coupling steps — makes methimazole highly effective at reducing hormone output.
• Gradual depletion of stored hormone: Methimazole does not affect thyroid hormone already stored in the gland or circulating in the bloodstream. The therapeutic effect comes from blocking new production, which allows existing hormone stores to be gradually depleted over days to weeks. This is why methimazole takes time to achieve euthyroid status — the body must clear the excess circulating hormone while new production is suppressed.

Why methimazole takes weeks to work: Unlike a drug that neutralizes an existing molecule (like an antihistamine blocking histamine receptors), methimazole prevents new hormone synthesis. The existing excess T3 and T4 in the circulation must be metabolized and cleared by the body — T4 has a half-life of approximately 7 days, and T3 about 1 day. This means that even with complete blockade of new production, it takes roughly 4 to 6 weeks for thyroid hormone levels to normalize, and clinical symptoms (tachycardia, tremor, heat intolerance, weight loss) typically improve over a similar timeframe. This pharmacokinetic reality is why antithyroid drugs are never a “quick fix” for hyperthyroidism — patience and consistent dosing are essential.

Pharmacokinetics: Methimazole is well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring 1 to 2 hours after oral administration. It has a relatively short plasma half-life of approximately 4 to 6 hours, but its pharmacodynamic effect (thyroid hormone suppression) lasts much longer because the TPO enzyme inhibition persists beyond plasma drug clearance. This is why once-daily or twice-daily dosing is effective despite the short plasma half-life. Methimazole is minimally metabolized by the liver and is primarily excreted unchanged by the kidneys. No dose adjustment is typically required for hepatic impairment.

FDA-Approved Indications and Common Clinical Uses

While methimazole is not FDA-approved specifically as a standalone drug product (it is available as a generic), its use is universally accepted and guideline-recommended for the following hyperthyroid conditions:

Graves’ Disease — First-Line Definitive Medical Therapy

Graves’ disease is the most common cause of hyperthyroidism, accounting for approximately 60-80% of cases. It is an autoimmune disorder in which thyroid-stimulating immunoglobulins (TSI) bind to and activate the TSH receptor on thyroid follicular cells, driving excessive hormone production, glandular hypertrophy, and often ophthalmopathy (Graves’ eye disease).

For Graves’ disease, methimazole serves as definitive medical therapy — meaning the drug itself, rather than radioactive iodine or surgery, is used to restore and maintain euthyroidism. Treatment courses typically last 12 to 18 months, with remission rates (defined as maintaining normal thyroid function for at least 12 months after stopping the drug) ranging from approximately 30% to 60% depending on the population studied, initial thyroid hormone levels, and TSI antibody titers. Factors associated with higher remission rates include milder disease at presentation, smaller goiter size, lower TSI levels, and the development of normalizing TSH levels during treatment.

The American Thyroid Association (ATA) guidelines recommend a titration approach (starting at a dose based on thyroid hormone levels and gradually reducing as euthyroidism is achieved) rather than a “block-and-replace” approach (high-dose antithyroid drug plus levothyroxine replacement) as the preferred strategy in most Graves’ disease patients, based on evidence that the titration approach achieves similar remission rates with fewer side effects and better TSH normalization.

Toxic Multinodular Goiter and Toxic Adenoma

In toxic multinodular goiter, multiple autonomously functioning thyroid nodules produce hormone independently of TSH regulation. In toxic adenoma, a single hyperfunctioning nodule is responsible. While radioactive iodine is often the definitive treatment of choice for these conditions (especially in older patients), methimazole is used as an initial therapy to control hyperthyroidism — either as a bridge to radioactive iodine, as definitive medical therapy in patients who are not candidates for radioactive iodine or surgery, or as long-term management in select cases.

Thyroid Storm — Acute Management (as part of multimodal therapy)

Thyroid storm is a life-threatening exacerbation of hyperthyroidism characterized by severe tachycardia, hyperthermia, altered mental status, and potential multi-organ failure. It is a medical emergency requiring intensive care management. In thyroid storm, methimazole (or PTU, which has the added benefit of blocking peripheral T4-to-T3 conversion) is used as part of a multimodal regimen that also includes beta-blockers (to control adrenergic symptoms), corticosteroids (to block T4-to-T3 conversion and manage relative adrenal insufficiency), iodide (to acutely block hormone release, given at least 1 hour after methimazole), and aggressive supportive care.

Preoperative Preparation for Thyroidectomy

For patients undergoing surgical thyroidectomy (for Graves’ disease, toxic multinodular goiter, or thyroid cancer), methimazole is used preoperatively to achieve euthyroidism. Operating on a hyperthyroid patient carries significant risks, including thyroid storm triggered by anesthesia and surgical manipulation. Achieving biochemical euthyroidism before surgery — typically over 4 to 6 weeks of methimazole titration — substantially reduces perioperative complications. In some protocols, iodine solution (Lugol’s or saturated solution of potassium iodide, SSKI) is added 7 to 10 days before surgery to further reduce gland vascularity and hormone release.

Dosing Guidelines: A Practical Approach

Methimazole dosing is individualized based on the severity of hyperthyroidism (free T4 and total T3 levels), the underlying etiology, and the therapeutic goal (rapid control vs. gradual normalization). The following table summarizes typical dosing strategies based on clinical guidelines.

Clinical Scenario	Initial Dose	Dose Adjustment Strategy	Target Duration	Monitoring
Graves’ disease — mild to moderate (FT4 1.5-2x ULN)	10-20mg once daily	Titrate down every 4-8 weeks as FT4 normalizes; goal is lowest effective dose	12-18 months (then trial off drug if remission suspected)	Free T4, total T3, TSH every 4-6 weeks initially; every 2-3 months once stable
Graves’ disease — severe (FT4 >2x ULN or high T3)	30-40mg once daily	Reduce dose as FT4 normalizes; transition to lower maintenance dose (5-15mg/day)	12-18 months	Free T4, total T3 every 2-4 weeks initially; TSH may remain suppressed for months
Toxic multinodular goiter — moderate	10-20mg once daily	Titrate based on free T4; long-term maintenance often needed	Variable (may be indefinite in some cases)	Free T4 every 4-8 weeks initially
Thyroid storm — adjunctive therapy	20-40mg every 6-8 hours (high dose)	Continue until storm resolves; transition to standard dosing	Acute episode management	Frequent thyroid function and clinical monitoring in ICU setting
Preoperative preparation	10-30mg once daily (based on FT4)	Titrate to euthyroidism over 4-6 weeks; add iodine 7-10 days pre-op	Until surgery	Free T4, total T3, TSH pre-op and as clinically indicated
Maintenance (after initial control achieved)	5-15mg once daily	Further reduction or discontinuation if remission suspected	3-6 months to assess for remission; longer if needed	Free T4 every 1-3 months

Key practical considerations for methimazole dosing:

• Take methimazole at the same time each day to maintain consistent drug levels. While its plasma half-life is short (4-6 hours), the pharmacodynamic effect on TPO is sustained, and consistent daily dosing maintains adequate enzyme inhibition.
• Food does not significantly affect absorption — methimazole can be taken with or without food. Consistency in administration timing relative to meals is more important than the presence or absence of food.
• TSH remains suppressed for months: Even after free T4 and total T3 normalize, TSH may remain undetectable or suppressed for 3 to 6 months (or longer) because the pituitary thyrotroph cells need time to recover from chronic suppression. Therefore, free T4 and total T3 — not TSH — should guide initial dose adjustments.
• Avoid overtreatment: Overly aggressive methimazole dosing can swing patients from hyperthyroidism to hypothyroidism, which then requires levothyroxine replacement. The goal is to normalize free T4 and total T3, not to suppress them below normal. In the titration approach, the dose should be reduced promptly when free T4 reaches the low-normal range.
• Radioactive iodine planning: If radioactive iodine (RAI) is planned after a course of methimazole, the drug should generally be stopped 3 to 7 days before RAI administration to maximize RAI uptake (methimazole can compete with RAI for uptake by the thyroid gland). In some protocols, methimazole is restarted a few days after RAI if thyroid hormone levels are still elevated, then gradually tapered over subsequent weeks to months.

Side Effects and Safety Monitoring

Methimazole is generally well-tolerated, but its side effect profile includes several important adverse effects that require vigilance — some of which are common and benign, while others are rare but potentially serious and mandate prompt medical attention.

Common (Minor) Side Effects — Usually Self-Limited

Approximately 5-10% of patients experience mild side effects that are typically self-limited and do not require drug discontinuation. These include:

• Skin rash (maculopapular): The most common side effect, occurring in approximately 2-5% of patients, usually within the first few weeks of treatment. The rash is typically mild, resolves spontaneously or with antihistamine treatment, and does not necessarily require discontinuation. However, if the rash is extensive, pruritic, or progressive, switching to PTU or another treatment approach may be considered.
• Pruritus (itching) without rash: Reported in approximately 1-2% of patients and usually transient.
• Arthralgia (joint pain): Mild joint aches reported by some patients, typically self-limited.
• GI upset (nausea, mild abdominal discomfort): Generally mild and often diminishes with continued use. Taking with food may help.
• Taste disturbance (dysgeusia): Uncommon but reported, usually transient.
• Hair loss (alopecia): Rare, but can occur — typically telogen effluvium type, which is usually temporary and resolves with continued treatment or drug discontinuation.

Agranulocytosis — The Most Serious Immediate Risk

Agranulocytosis — a severe, potentially life-threatening drop in white blood cell count (absolute neutrophil count, ANC, below 500 cells/µL) — is the most feared adverse effect of methimazole. It occurs in approximately 0.2% to 0.5% of patients (roughly 2 to 5 cases per 1,000 treated patients), typically within the first 3 months of treatment. The clinical presentation is usually acute: high fever, severe sore throat, and signs of infection (tonsillitis, pharyngitis, or systemic sepsis) in a patient recently started on methimazole.

Critical patient instruction — “Stop and call immediately”: Every patient starting methimazole must be explicitly instructed that if they develop a fever (especially with sore throat, mouth ulcers, or any signs of infection), they must stop methimazole immediately and seek urgent medical evaluation with a complete blood count (CBC) with differential. This is a medical emergency — agranulocytosis can progress rapidly to sepsis and death if not recognized and treated promptly. The drug should not be restarted until the ANC has recovered to a safe level (typically >1,500 cells/µL). In most cases, once agranulocytosis occurs, methimazole must be permanently discontinued and an alternative treatment (PTU with caution, radioactive iodine, or surgery) pursued. Cross-reactivity between methimazole and PTU for agranulocytosis is significant (approximately 10-20%), so PTU is not necessarily a safe alternative after methimazole-induced agranulocytosis.

Baseline CBC with differential and differential is recommended before starting methimazole, though routine monitoring of CBC during treatment is not universally recommended for asymptomatic patients — because agranulocytosis is typically acute and idiosyncratic rather than dose-dependent and predictable. Instead, patient education about the warning signs and the imperative to stop the drug and seek immediate care is the primary safety strategy.

Other Serious (Rare) Adverse Effects

• Hepatotoxicity: Methimazole can cause liver injury, though significantly less frequently than PTU. Most cases are mild, transient transaminase elevations that resolve with continued therapy or dose reduction. Severe hepatotoxicity (fulminant hepatic failure) is extremely rare with methimazole — much less common than with PTU. Baseline liver function tests (LFTs) are reasonable before starting therapy, and LFT monitoring should be guided by clinical suspicion.
• Vasculitis (ANCA-positive): Methimazole has been associated with ANCA-positive vasculitis, a rare immune-mediated condition that can affect multiple organs. The presentation can include fever, skin rash, peripheral neuropathy, lung infiltrates, and kidney involvement. This is extremely rare (case reports) and typically occurs after prolonged therapy. ANCA titers can be monitored if vasculitis is suspected.
• Aplastic anemia: Extremely rare, but reported. Would present with pancytopenia rather than isolated neutropenia. Requires immediate drug discontinuation and hematology consultation.
• Teratogenicity: Methimazole is associated with a specific pattern of birth defects — the “Methimazole embryopathy” — characterized by aplasia cutis congenita (absence of skin on the scalp), choanal atresia, tracheoesophageal fistula, omphalocele, and other midline defects. The absolute risk is low (estimated at approximately 1-2% of first-trimester exposures), but clinically significant. Because of this risk, PTU is preferred over methimazole during the first trimester of pregnancy (with a switch back to methimazole in the second trimester if appropriate, due to PTU’s hepatotoxicity risk), or definitive treatment (radioactive iodine or surgery) should be completed before pregnancy. Women of childbearing potential should be counseled about this risk and should use effective contraception while on methimazole.
• Hypothyroidism: The intended effect of therapy overshooting — over-treatment leads to iatrogenic hypothyroidism, which is readily managed with levothyroxine replacement and dose adjustment, but is an important consideration during prolonged therapy.

Methimazole vs. Propylthiouracil (PTU): Which to Choose?

PTU was historically the mainstay of antithyroid therapy, but methimazole has largely superseded it as the first-line agent due to its superior safety profile. The key differences are summarized below:

Attribute	Methimazole	Propylthiouracil (PTU)
Dosing frequency	Once or twice daily	Three times daily (shorter half-life)
Hepatotoxicity risk	Low (rare severe hepatic failure)	Higher — black box warning for severe liver injury in children and adults
Agranulocytosis risk	~0.2-0.5%	~0.2-0.5% (similar risk)
Peripheral T4→T3 conversion blockade	None (does not block peripherally)	Yes — blocks Type 1 deiodinase, reducing T3 production from T4
Preferred in first-trimester pregnancy	No — teratogenic risk	Yes — preferred despite hepatotoxicity concern
Preferred in thyroid storm	Can be used; PTU has added advantage	Preferred (blocks T4→T3 conversion)
Preferred in methimazole intolerance	N/A	Considered with caution (hepatotoxicity risk)
IU : mg potency	10:1 (10mg methimazole ≈ 100mg PTU)	—
Plasma half-life	4-6 hours	1-2 hours

Monitoring During Methimazole Therapy

Effective methimazole therapy requires structured monitoring to track thyroid function, detect adverse effects, and guide dose adjustments. A typical monitoring schedule includes:

• Thyroid function tests: Free T4 and total T3 (or free T3 where available) should be checked every 4-6 weeks after starting or adjusting the dose, as these provide the most direct assessment of thyroid hormone status. TSH is unreliable as a monitoring tool during the initial months because it remains suppressed even as T4 and T3 normalize. Once free T4 and total T3 have been consistently normal and TSH has begun to recover (usually after 3-6 months), TSH can be incorporated into routine monitoring.
• Complete blood count (CBC) with differential: Baseline CBC is recommended before starting therapy. Routine serial CBC monitoring is not required for all patients, but should be performed immediately if the patient develops fever or symptoms suggestive of infection (to rule out agranulocytosis).
• Liver function tests (LFTs): Baseline LFTs are recommended. Routine serial monitoring is not universally required, but LFTs should be checked if the patient develops symptoms suggestive of liver injury (jaundice, dark urine, right upper quadrant pain, unexplained fatigue, nausea).
• TSI / TRAb antibody testing: Thyroid-stimulating immunoglobulin (TSI) or TSH receptor antibody (TRAb) levels can be helpful for prognosis. Patients with high or persistently elevated TSI/TRAb levels at the end of a 12-18 month treatment course have a higher risk of relapse after stopping methimazole — in such cases, extended treatment duration or alternative definitive therapy (radioactive iodine or surgery) may be considered.
• Clinical monitoring: Regular assessment of heart rate, weight, tremor, skin findings (especially Graves’ dermopathy), and ocular symptoms is essential. Improvement in these clinical parameters confirms biochemical response and treatment effectiveness.

Cost Considerations: US Brand vs. Indian Generic Methimazole

As with many chronic medications, the long-term cost of methimazole can be a significant factor — particularly for patients who require 12 to 18 months (or longer) of consistent daily therapy. Understanding the pricing landscape helps patients make informed financial decisions alongside their clinical ones.

US pricing context: In the United States, generic methimazole is widely available at reasonable cost through most pharmacy benefit managers and retail pharmacies. Cash prices for a 30-day supply of generic methimazole (5mg, 10mg, or 20mg tablets) typically range from approximately $10 to $30 depending on the pharmacy, manufacturer, and quantity. Insurance copays are often minimal (commonly $0 to $10). However, for patients without insurance or with high deductibles, the cost can accumulate over a 12-18 month treatment course, and brand-name Tapazole (when still available) would be substantially more expensive.

India generic pricing context: Indian generic pharmaceutical manufacturers produce methimazole at prices that reflect the country’s competitive generic manufacturing market. For patients able to access these generics through legitimate channels, the cost can be dramatically lower — often representing savings of approximately 70-90% compared to US brand-name pricing. This is consistent with the broader pattern seen across many generic medications manufactured in India, where competitive manufacturing markets and lower operational costs translate into affordable end-consumer prices.

Ensuring quality when sourcing internationally: Patients considering Indian generic methimazole should verify that the manufacturer follows Good Manufacturing Practices (GMP) and holds applicable regulatory certifications (such as WHO-GMP or certifications from national regulatory agencies). Reputable online generic pharmacies will provide information about the manufacturer, the specific product’s regulatory status, and quality documentation. Patients should be cautious of sources that do not provide transparent product information, lack verifiable contact details, or offer prices that seem implausibly low.

For patients interested in exploring affordable generic options, our Thyroid Disorders product category provides information on available methimazole generics and related thyroid medications at competitive prices.

Frequently Asked Questions

Q: How long does methimazole take to normalize thyroid levels?
A: Most patients begin to feel symptom improvement (reduced heart rate, less tremor, improved energy) within 1 to 3 weeks of starting methimazole. Free T4 and total T3 levels typically normalize within 4 to 8 weeks, though this depends on the severity of initial hyperthyroidism and the starting dose. TSH may remain suppressed for 3 to 6 months or longer even after T4 and T3 normalize. This is expected — TSH recovery lags behind thyroid hormone normalization — and does not indicate treatment failure.

Q: Can I stop methimazole when I feel better?
A: No. Feeling better reflects that thyroid hormone levels are normalizing — but stopping methimazole prematurely will allow the underlying hyperthyroidism to recur, often within weeks to months. The standard treatment course for Graves’ disease is 12 to 18 months, with a trial of discontinuation only after thyroid function has been stable on a low maintenance dose for a reasonable period. Abrupt discontinuation without medical supervision risks rapid recurrence of hyperthyroidism and potential thyroid storm in severe cases.

Q: What are the signs of agranulocytosis and what should I do?
A: The hallmark signs are sudden onset of fever (usually >38.5°C / 101.3°F) accompanied by severe sore throat, mouth ulcers, or other signs of infection. This typically occurs within the first 3 months of treatment. If these symptoms occur, stop methimazole immediately and go to an urgent care or emergency department for a complete blood count with differential — do not wait for a routine appointment. Agranulocytosis is a medical emergency that requires prompt antibiotics and discontinuation of methimazole.

Q: Is methimazole safe during pregnancy?
A: This is a nuanced question. Methimazole is associated with a specific pattern of birth defects (Methimazole embryopathy) when exposure occurs during the first trimester. For this reason, PTU is generally preferred during the first trimester (weeks 1-13), with a transition back to methimazole in the second trimester due to PTU’s higher hepatotoxicity risk. In the second and third trimesters, methimazole is generally considered acceptable. Women who are planning pregnancy or discover they are pregnant while on methimazole should consult their endocrinologist immediately — medication adjustments should be made under medical supervision, not by self-discontinuation.

Q: Will methimazole cure my Graves’ disease?
A: “Cure” in the context of Graves’ disease means achieving durable remission — maintaining normal thyroid function after stopping the medication. With a standard 12-18 month course of methimazole, approximately 30-60% of patients achieve remission, with the remaining 40-70% experiencing relapse within 1-2 years of stopping the drug. Factors that predict higher remission rates include milder disease at presentation, smaller goiter, lower TSI antibody levels, and smoking cessation (smoking is associated with higher relapse rates and worse Graves’ ophthalmopathy). Patients who relapse can be retreated with methimazole, treated with radioactive iodine, or undergo surgery.

Q: Can methimazole cause weight gain?
A: Weight changes on methimazole are primarily due to the correction of the hyperthyroid state. Hyperthyroidism typically causes weight loss (due to increased metabolic rate), and as thyroid hormone levels normalize, patients often regain lost weight — which is a healthy restoration rather than pathological weight gain. Some patients do report modest weight gain beyond weight restoration, possibly due to a relative shift from a hypermetabolic to a normal metabolic state, but significant weight gain attributable to methimazole itself (independent of thyroid normalization) is uncommon. If weight changes are a concern, discussing dietary and lifestyle strategies with a healthcare provider is reasonable.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Methimazole is a prescription medication that requires careful monitoring by a qualified healthcare provider — typically an endocrinologist or primary care physician with endocrinology expertise. The information provided here is intended to help patients understand their treatment, but it should not replace individualized medical guidance. Always consult with your doctor before starting, stopping, or adjusting any medication. Thyroid disorders require regular monitoring of thyroid function, and dose adjustments should only be made under medical supervision. Price ranges are approximate and subject to market fluctuations; actual costs vary by manufacturer, dosage, quantity, and location of purchase.

References

• American Thyroid Association (ATA). Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(6):1-128.
• Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism. Thyroid. 2016;26(10):1343-1421.
• Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(8):561-598.
• Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725-1735.
• Lazarus JH. Management of hyperthyroidism. Clin Med. 2016;16(2):170-173.
• Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):904-915.
• Laurberg P, et al. High incidence of persistent hyperthyroidism after 18 months of medical therapy for Graves’ disease. Eur J Endocrinol. 2008;159(1):1-7.
• Nyirenda MJ, et al. Randomised trial of 12 months versus 6 months of treatment for Graves’ disease. Lancet. 2005;366(9481):200-205.
• Puustinen L, et al. Long-term treatment of Graves’ disease with methimazole. Thyroid. 2013;23(9):1069-1077.
• Homatidis S, et al. The effect of smoking on methimazole dose in Graves’ disease. Thyroid. 2004;14(6):481-485.
• Vasudevan N, et al. Safety profile of methimazole versus propylthiouracil: a meta-analysis. Thyroid. 2015;25(5):279-289.